Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QW50
Thu, 12.11.2020
Epigenomics AG
Epigenomics AG reports financial results for the first nine months of 2020
Berlin (Germany) and San Diego, CA (U.S.A.), November 12, 2020 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2020.
Major Events after the End of the Reporting Period
On October 16, [ … ]
Mon, 26.10.2020
Epigenomics AG
Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG
Berlin, October 26, 2020 - The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the Company has been incurred. This anticipated de [ … ]
Mon, 19.10.2020
Epigenomics AG
Epigenomics AG hosts conference call on preliminary CMS reimbursement decision
Berlin (Germany) and San Diego, CA (USA), October 19, 2020 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") is appalled and vehemently disagrees with the negative, preliminary reimbursement proposal by the U.S. Centers for Medicare & Med [ … ]
Mon, 31.08.2020
Epigenomics AG
CMS Still Actively Working on Proposed Decision Memo with Goal to Publish As Soon As Possible
Berlin (Germany) and San Diego, CA (USA), August 31, 2020 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that the Centers for Medicare & Medicaid Services (CMS) did not issue the proposed decision memo for its [ … ]
Thu, 13.08.2020
Epigenomics AG
Epigenomics AG presents operational highlights and reports financial results for first six months of 2020
Berlin (Germany) and San Diego, CA (U.S.A.), August 13, 2020 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported operational highlights and financial results for the second quarter and first half of 2020.
Operational highl [ … ]
Mon, 10.08.2020
Epigenomics AG
New study published in the Journal of the National Cancer Institute concludes that Epi proColon(R) is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening
Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases aver [ … ]